TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29526236
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets similar to Amla prescription
Study: 26922847
Drug: Conventional TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional TENS therapy for 20 minutes
Study: 26922847
Drug: Sham TENS
Normalized name: TEN
DrugBank: Pentaerythritol tetranitrate (DB06154)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TENS therapy
Study: 23107591
Drug: Fluvirin inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvirin inactivated vaccine
Study: 23107591
Drug: Fluarix inactivated
Normalized name: Fluarix 2024-2025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluarix inactivated vaccine
Study: 20552817
Drug: Complex Decongestive
Normalized name: Qlearquil Nasal Decongestant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex Decongestive Therapy (CDT) alone
Study: 15957137
Drug: High-energy and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy and high-protein supplementation (an extra 475 kcal and 16.6 g of protein daily; group A; n = 12)
Study: 10444320
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral and written instructions
Study: 7778152
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether 300 mg on the first day, mefloquine 750 mg at 24 h, and 500 mg at 30 h (group A)
Study: 7778152
Drug: Oral artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral artemether 300 mg on the first day, mefloquine 750 mg at 24 h, and placebo at 30 h (group B)
Study: 19297212
Drug: Aspirin (75mg)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (75mg) and cilostazol (100mg twice daily)
Study: 16176310
Drug: Computer preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer preparation package
Study: 16176310
Drug: Cartoon preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cartoon preparation package
Study: 8912110
Drug: Therapeutic community
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic community principles applied in acute care psychiatric treatment program
Study: 7201645
Drug: Bromocriptine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (1.25 mg twice daily) for 3 cycles
Study: 18389193
Drug: Topical 0.4%
Normalized name: fluoride topical 0.4% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.4% glycerol trinitrate
Study: 18389193
Drug: Topical 2%
Normalized name: menthol topical 2% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 2% calcium blocker
Study: 17319449
Drug: OxyContin (O-ER),
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxyContin (O-ER), oxycodone modified-release tablets given twice a day
Study: 14748822
Drug: Posaconazole suspension
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole suspension (200 mg/5 ml) with a high-fat meal
Study: 14748822
Drug: Posaconazole suspension
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole suspension (200 mg/5 ml) in fasting state
Study: 14748822
Drug: Posaconazole suspension
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole suspension (200 mg/5 ml) with a nonfat meal
Study: 14748822
Drug: Posaconazole tablets
Normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Posaconazole tablets (2 x 100 mg) with a high-fat meal
Study: 9140689
Drug: EGb 761
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGb 761 (Tanakan, 320 mg/day, n = 8)
Study: 7948798
Drug: 0.03% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03% bupivacaine with fentanyl (4 micrograms/mL)
Study: 7948798
Drug: 0.06% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.06% bupivacaine with fentanyl (4 micrograms/mL)
Study: 7948798
Drug: 0.125% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125% bupivacaine with fentanyl (4 micrograms/mL)
Study: 6219578
Drug: Oral phosphate
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral phosphate
Study: 16651463
Drug: Nicotine (4‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (4‐mg tablet)
Study: 11191007
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg tid intravenously plus octreotide 100 micrograms tid subcutaneously for three days (Group B: 40 patients)
Study: 11191007
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg tid intravenously alone (Group A)
Study: 11191007
Drug: Ranitidine 50
Normalized name: ranitidine 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 50 mg tid intravenously plus octreotide 100 micrograms tid subcutaneously for three days (Group B)
Study: 31113646
Drug: Positive 25
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Positive 25 g fructose breath test
Study: 24612976
Drug: Successful antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful antimicrobial treatment
Study: 22691757
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin chemoradiotherapy supplemented with concurrent gemcitabine and adjuvant gemcitabine/cisplatin
Study: 22691757
Drug: Concurrent cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent cisplatin chemoradiotherapy
Study: 19438846
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg mesalazine three times daily for 8 weeks
Study: 17519064
Drug: C.E.R.A. (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. (continuous erythropoietin receptor activator) administered subcutaneously once monthly (Q4W)
Study: 17519064
Drug: C.E.R.A. (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: C.E.R.A. (continuous erythropoietin receptor activator) administered subcutaneously
Study: 17519064
Drug: Epoetin therapy
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin therapy administered 1-3 times/week (previous treatment before switching to C.E.R.A.)
Study: 9709770
Drug: Topical instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical instillation of 2% dorzolamide hydrochloride
Study: 7557064
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution drops, one drop every 12 hours for seven days
Study: 30852136
Drug: Full-dose monotherapy
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose monotherapy with S-1 (30 mg/m2 orally twice daily on days 1–14 every 3 weeks)
Study: 30852136
Drug: Full-dose monotherapy
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose monotherapy with S-1
Study: 30852136
Drug: Reduced-dose combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose combination chemotherapy with S-1 and oxaliplatin
Study: 25363733
Drug: Intravenous paricalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous paricalcitol injection
Study: 25363733
Drug: Intravenous maxacalcitol
Normalized name: Paricalcitol
DrugBank: Paricalcitol (DB00910)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous maxacalcitol injection
Study: 16312178
Drug: QD arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD arm (high didanosine doses)
Study: 16312178
Drug: QD arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: QD arm (individuals with HIV-1 RNA <400 copies/ml)
Study: 29809075
Drug: SHP465 mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHP465 mixed amphetamine salts (MAS) 50 or 75 mg
Study: 29809075
Drug: Immediate-release MAS
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release MAS (MAS IR) 25 mg
Study: 27168455
Drug: Fermented milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fermented milk product (100 g, twice daily for 3 months)
Study: 23070058
Drug: PAF-R antagonist
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAF-R antagonist CV3988
Study: 20884953
Drug: Therapist-delivered online
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapist-delivered online cognitive-behavioural therapy (CBT)
Study: 10690133
Drug: rapacuronium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: rapacuronium 1.5 mg kg‐1
Study: 8738686
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg kg‐1
Study: 1842141
Drug: Diltiazem (270
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (270 mg/day for 3 weeks)
Study: 2869618
Drug: Surgical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical therapy (coronary artery bypass surgery)
Study: 23063316
Drug: Ciclosporin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciclosporin (2 mg/kg per day for 1 week, followed by oral drug until day 98)
Study: 15467292
Drug: Antibiotics (ampicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (ampicillin and gentamicin for 3 days)
Study: 7884123
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (standard district nurse-administered services at home)
Study: 24906587
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules daily)
Study: 30760332
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy consisting of Acticoat™ and Mepitel™
Study: 25803441
Drug: CPIA (continuous
Approvals — FDA: no, EMA: no, PMDA: no
Description: CPIA (continuous propofol infusion by anesthesiologist)
Study: 25803441
Drug: IMIE (intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMIE (intermittent midazolam/propofol injection by endoscopist)
Study: 23969308
Drug: Decitabine therapy
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine therapy with dose delays or dose reductions (DD/DR) after achieving best objective response.
Study: 19089438
Drug: Betamethasone treatment
Normalized name: Betamethasone
DrugBank: Betamethasone phosphate (DB14669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone treatment (intramuscular injection of 12 mg every 24 hours)
Study: 11508513
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) and Placebo
Study: 2906953
Drug: Propranolol (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (acute and chronic treatment)
Study: 2906953
Drug: i.v. Metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. Metoprolol (acute treatment)
Study: 27435163
Drug: Metformin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 1,000 mg twice daily
Study: 21978861
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow oxygen therapy
Study: 21978861
Drug: Standard oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard oxygen therapy (2-4 L/min via simple facemask or nasal cannulae)
Study: 10950043
Drug: Misoprostol rectal
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol rectal suppositories (200 microg tablets, 1 h before each radiation session)
Study: 3918431
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g of beta-galactosidase from Kluyveromyces lactis
Study: 3806896
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy (one short course)
Study: 9063317
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (control group)
Study: 31606589
Drug: Lofexidine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lofexidine (all doses)
Study: 28442303
Drug: High-dose ropinirole
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ropinirole CR (18-24 mg/day)
Study: 28442303
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between high-dose and maintenance groups
Study: 23622849
Drug: Remission (achieved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remission (achieved by either treatment)
Study: 12149660
Drug: rilmenidine therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: rilmenidine therapy
Study: 29746373
Drug: droperidol 0.625
Normalized name: droPERidol 0.625 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: droperidol 0.625 mg
Study: 7614176
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of twice daily Peridex rinse (0.12% chlorhexidine gluconate) after surgery
Study: 7614176
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (group 1)
Study: 2109558
Drug: Parenteral tobramycin
Normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parenteral tobramycin and ticarcillin (n = 7)
Study: 20682881
Drug: Miltefosine, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine, 50 mg capsule taken orally three times per day for 28 days
Study: 19080711
Drug: Preoperative chemotherapy
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemotherapy group
Study: 16882108
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Pioglitazone
Study: 10591284
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (medication management + intensive behavioral treatment)
Study: 8693597
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with two courses of cisplatin (120 mg/m2 i.v. day one) plus bleomycin (20 mg/m2/day for 5 consecutive days in 24-hr i.v. perfusion) followed by definitive surgery and postoperative radiation therapy
Study: 8693597
Drug: Surgery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery plus postoperative radiation therapy (50-60 Gy)
Study: 31537219
Drug: Mild hypothermia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild hypothermia (after 72 hours of treatment at 32-35 centigrade, increasing about 1 centigrade every 6 hours until normal temperature)
Study: 19136164
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g of intravenous magnesium sulfate
Study: 9028511
Drug: 1000 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 micrograms of inhaled beclomethasone dipropionate
Study: 9028511
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of oral prednisone
Study: 9028511
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms of inhaled beclomethasone dipropionate
Study: 9028511
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of oral prednisone
Study: 9028511
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of oral prednisone
Study: 1900480
Drug: 10 mg/d
Normalized name: Arixtra 10 mg/dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/d of RU486 for 4 days from the date of ovulation
Study: 6872419
Drug: Metkephamid 140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metkephamid 140 mg
Study: 3540872
Drug: Meperidine 100
Normalized name: meperidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meperidine 100 mg
Study: 6872419
Drug: Metkephamid 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metkephamid 70 mg
Study: 24356952
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (300,000 IU single oral bolus)
Study: 24511232
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment group
Study: 23518872
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin plus glycoprotein IIb/IIIa inhibitor
Study: 8886213
Drug: Naprosyn 500
Normalized name: Naprosyn 500mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naprosyn 500 mg BID
Study: 6306179
Drug: Dibromodulcitol (DBD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dibromodulcitol (DBD) during radiotherapy followed by combination chemotherapy of CCNU and DBD
Study: 28241037
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG‐ELP (group A)
Study: 28241037
Drug: 2 L
Normalized name: H-2 locus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L PEG‐ELP (group C)
Study: 22656865
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (CR) 25x2 Gy/5 weeks plus sequential boost 8x2 Gy/2 weeks (cumulative dose 66 Gy/7 weeks)
Study: 11289051
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg retard twice daily
Study: 232314
Drug: Continued cyclical
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued cyclical chemotherapy
Study: 232314
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further chemotherapy until relapse
Study: 232314
Drug: Chemotherapy (cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cyclophosphamide, vincristine, procarbazine, methotrexate)
Study: 232314
Drug: Radiotherapy or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy or palliative treatment for non-responders
Study: 232314
Drug: Indicators of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indicators of non-response to chemotherapy
Study: 31358390
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use (propensity score matched)
Study: 31358390
Drug: Aspirin use
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin use (quintile 5)
Study: 31358390
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-users of aspirin)
Study: 28273894
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) injection (3 mL)
Study: 19136481
Drug: Patient-Delivered Partner
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Delivered Partner Therapy (PDPT) - 1 g azithromycin for partners
Study: 31262226
Drug: Moderate-to-severe PsO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-to-severe PsO patients with treated anxiety/depression (≥1 anxiety or depression diagnosis plus any anxiolytics, antidepressants, or antipsychotics within 30 days)
Study: 19478638
Drug: Dynamic enhanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic enhanced computed tomography (CT) after neoadjuvant chemotherapy
Study: 17927495
Drug: Lycopene alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene alone (15 mg)
Study: 17927495
Drug: Lycopene plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene plus soy isoflavones (40 mg)
Study: 15843228
Drug: Stress doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stress doses of hydrocortisone
Study: 9246023
Drug: Carbamazepine 800
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine 800 mg
Study: 24247410
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg bolus, followed by an infusion of 1.5 μg/kg/min)
Study: 10658943
Drug: Valsartan (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80-160 mg/day orally)
Study: 10658943
Drug: Enalapril (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (20-40 mg/day orally)
Study: 2225430
Drug: Deferoxamine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferoxamine (30 mg/kg body weight intravenously starting 30 minutes before bypass for 4 hours and 250 mg/l in cardioplegic solution)
Study: 2225430
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no deferoxamine treatment)
Study: 518286
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) at a daily dose of 120 mg for 8 weeks
Study: 15526719
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone deficiency (GHD) patients
Study: 3110562
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate (E2V) daily for 6 weeks
Study: 3110562
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg oestradiol valerate (E2V) daily for 6 weeks
Study: 3110562
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate (E2V) daily for 3 months
Study: 3110562
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg oestradiol valerate (E2V) daily for 3 months
Study: 30369076
Drug: WCK 2349
Normalized name: Wck 771 free base
DrugBank: Levonadifloxacin (DB16219)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WCK 2349 (2,600 mg)
Study: 23531328
Drug: EPA-rich fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA-rich fish oil (1060 mg EPA plus 274 mg DHA)